Table 4.
Clinical parameters in relation to NLR.
| NLR ≤ 3.74 (n = 49) | NLR > 3.74 (n = 69) | P value | |
|---|---|---|---|
| Age, median (range) | 72 (46–93) | 74 (53–94) | 0.512 |
| Gender (female/male) | 25/24 | 31/38 | 0.641 |
| Tumor location (head/body or tail) | 24/25 | 24/45 | 0.175 |
| cStage (locally advanced/metastatic) | 12/37 | 2/67 | 0.001 |
| Treatment (present/absent) | 38/11 | 43/26 | 0.120 |
| ECOG-PS (≤ 1/ > 1) | 44/5 | 40/29 | < 0.001 |
| GPS (0/1/2) | 30/12/6 | 12/30/27 | < 0.001 |
| Modified GPS (0/1/2) | 34/8/6 | 16/26/27 | < 0.001 |
| PLR, median (range) | 128.10 (38.50–267.98) | 202.01 (60.96–655.41) | < 0.001 |
| CRP/Alb ratio, median (range) | 0.06 (0.00–2.39) | 0.87 (0.03–12.34) | < 0.001 |
| PNI, median (range) | 48.35 (34.60–61.96) | 39.52 (24.25–51.51) | < 0.001 |
NLR neutrophil-to-lymphocyte ratio; GPS Glasgow Prognostic Score; PLR platelet-to-lymphocyte ratio; CRP C-reactive protein; Alb albumin; PNI prognostic nutritional index.